



## **Appendix 4C – March 2019 Quarter**

**Brisbane, Australia 24 April 2019:** Factor Therapeutics Limited (ASX: FTT) has released its Appendix 4C for the March 2019 Quarter.

The Company held cash reserves at the end of the quarter of \$4.404 million. Operating cash outflows during the quarter totalled \$1.118 million.

Of this amount, ~\$612k was spent on direct R&D activities, being costs associated with the completed Phase 2b clinical trial of VF001; ~\$97k related to staff costs, including accrued leave and other costs associated with the termination of employment contracts of former employees; and ~\$409k was spent on corporate and administration costs including costs associated with the cessation of leases including makegood (\$142k), bank fees, compliance/ accounting/ R&D tax consulting/ audit fees (\$90k), life sciences insurances (\$42k), legal, ASIC, ASX and registry costs (\$87k) and patent fees (\$40k).

During the quarter, a total of \$2.529 million was received in government grants and incentives.

\$2.488 million of this amount was the R&D tax incentive rebate received for eligible R&D activities undertaken in the financial year ended 31 December 2018. A further \$0.041 in AusIndustry Grants was received during the Quarter for work undertaken in FY18 on VF001.

Following the Phase 2b trial result the Company has managed the orderly completion of previous research and development activities and implemented significant cost minimisation initiatives. The Company's current focus is on maintaining its intellectual property portfolio while the Board completes assessment of a number of opportunities, including potential new technology acquisitions, and the Company's future direction.

Costs associated with these assessments and due diligence activities were paid subsequent to the end of the quarter. As the Company is still yet to receive full and final invoices from some suppliers in relation to the completed Phase 2b clinical trial of VF001, forecast R&D spend for the June Quarter continues to relate to costs associated with the completed Phase 2b clinical trial.

**-ENDS-**

### **Further Information:**

Melanie Farris, Company Secretary  
Factor Therapeutics Limited  
[m.farris@factor-therapeutics.com](mailto:m.farris@factor-therapeutics.com)

## Appendix 4C

### Quarterly report for entities subject to Listing Rule 4.7B

Introduced 31/3/00. Amended 30/9/01, 24/10/05, 17/12/10, 1/09/16

**Name of entity**

FACTOR THERAPEUTICS LIMITED

**ABN**

45 101 955 088

**Quarter ended ("current quarter")**

31-March-2019

**Consolidated statement of cash flows**

**1. Cash flows from operating activities**

	Current quarter \$A'000	Year to date (3 months) \$A'000
1.1 Receipts from customers	5	5
1.2 Payments for		
(a) research and development	(612)	(612)
(b) product manufacturing and operating costs	-	-
(c) advertising and marketing	-	-
(d) leased assets	-	-
(e) staff costs	(97)	(97)
(f) administration and corporate costs	(409)	(409)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	1	1
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	2,529	2,529
1.8 Other (provide details if material)	12	12
Bond refund		
<b>1.9 Net cash from/(used in ) operating activities</b>	<b>1,429</b>	<b>1,429</b>

**2. Cash flows from investing activities**

2.1 Payments to acquire:		
(a) property, plant and equipment	-	-
(b) businesses (see item 10)	-	-
(c) investments	-	-

<b>Consolidated statement of cash flows</b>		<b>Current quarter</b>	<b>Year to date</b>
		<b>\$A'000</b>	<b>(3 months) \$A'000</b>
	(d) intellectual property	-	-
	(e) other non-current assets	-	-
2.2	Proceeds from disposal of:		-
	(a) property, plant and equipment	-	-
	(b) businesses (see item 10)	-	-
	(c) investments	-	-
	(d) intellectual property	-	-
	(e) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	<b>Net cash from/(used in ) investing activities</b>	-	-
<b>3. Cash flows from financing activities</b>			
3.1	Proceeds from issues of shares	417	417
3.2	Proceeds from issue of convertible notes	-	-
3.3	Proceeds from exercise of share options	-	-
3.4	Transaction costs related to issues of shares, convertible notes or options	(28)	(28)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	<b>Net cash from/(used in ) financing activities</b>	<b>389</b>	<b>389</b>
<b>4. Net increase / (decrease) in cash and cash equivalents for the period</b>			
4.1	Cash and cash equivalents at beginning of quarter/year to date	2,598	2,598
4.2	Net cash from / (used in) operating activities (item 1.9 above)	1,429	1,429
4.3	Net cash from / (used in) investing activities (item 2.6 above)	-	-
4.4	Net cash from / (used in) financing activities (item 3.10 above)	389	389

<b>Consolidated statement of cash flows</b>		<b>Current quarter</b>	<b>Year to date</b>
		<b>\$A'000</b>	<b>(3 months) \$A'000</b>
4.5	Effect of movement in exchange rates on cash held	(12)	(12)
4.6	<b>Cash and cash equivalents at end of quarter</b>	<b>4,404</b>	<b>4,404</b>

<b>5. Reconciliation of cash and cash equivalents</b>	<b>Current quarter</b>	<b>Previous quarter</b>
at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	<b>\$A'000</b>	<b>\$A'000</b>
5.1 Bank Balances	4,262	14
5.2 Call deposits	142	2,584
5.3 Bank overdrafts	-	-
5.4 Other (provide details)	-	-
5.5 <b>Cash and cash equivalents at end of quarter (should equal item 4.6 above)</b>	<b>4,404</b>	<b>2,598</b>

<b>6. Payments to directors of the entity and their associates</b>	<b>Current quarter</b>
	<b>\$A'000</b>
6.1 Aggregate amount of payments to the parties included in item 1.2	-
6.2 Aggregate amount of cash flow from loans to these parties included in item 2.3	-
6.3 Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2	
Payments to directors includes directors fees and executive directors salaries.	

<b>7. Payments to related entities of the entity and their associates</b>	<b>Current quarter</b>
	<b>\$A'000</b>
7.1 Aggregate amount of payments to the parties included in item 1.2	-
7.2 Aggregate amount of cash flow from loans to these parties included in item 2.3	-
7.3 Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2	

**8. Financing facilities available**  
*Add notes as necessary for an understanding of the position*

- 8.1 Loan facilities  
8.2 Credit standby arrangements  
8.3 Other (please specify)

Total facility amount at quarter end \$A'000	Total drawn at quarter end \$A'000
-	-
-	-
-	-

- 8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.

--

**9. Estimated cash outflows for next quarter**

- 9.1 Research and development  
9.2 Product manufacturing and operating costs  
9.3 Advertising and marketing  
9.4 Leased assets  
9.5 Staff costs  
9.6 Administration and corporate costs  
9.7 Other - Transaction costs related to issue of shares  
9.8 **Total estimated cash outflows**

\$A'000
1,097
-
-
-
341
-
1,438

**10. Acquisitions and disposals of business entities  
(items 2.1(b) and 2.2(b) above)**

- 10.1 Name of entity  
10.2 Place of incorporation or registration  
10.3 Consideration for acquisition or disposal  
10.4 Total net assets  
10.5 Nature of business

Acquisitions	Disposals
N/A	N/A

**Compliance statement**

<sup>1</sup> This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

<sup>2</sup> This statement gives a true and fair view of the matters disclosed.

Sign here: Original signed  
(Company Secretary)



Date: 24-April-2019

Print name: Melanie Farris

**Notes**

- 1 The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.
- 2 If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
- 3 Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.